Antisynthetase Syndrome and Pleural Effusion: A Case Report

Chen, Lucas; Somers, Aba; Liu, Jessica

doi:10.1016/j.chest.2020.08.1725

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other case reports show a similar sterile exudative pleural effusion that resolves when the disease activity is controlled, suggesting an element of ASySmediated pleuritis. [114][115][116][117] Interestingly, in an extensive retrospective analysis for evidence of serositis in ASyS, 93 patients were isolated. 118 Pleural effusions were present in 44% of patients, 75% of which were bilateral.…”

Section: Pleural Diseasementioning

confidence: 99%

Review of Pulmonary Manifestations in Antisynthetase Syndrome

Ghanbar,

Danoff

2024

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Antisynthetase syndrome (ASyS) is now a widely recognized entity within the spectrum of idiopathic inflammatory myopathies. Initially described in patients with a triad of myositis, arthritis, and interstitial lung disease (ILD), its presentation can be diverse. Additional common symptoms experienced by patients with ASyS include Raynaud's phenomenon, mechanic's hand, and fever. Although there is a significant overlap with polymyositis and dermatomyositis, the key distinction lies in the presence of antisynthetase antibodies (ASAs). Up to 10 ASAs have been identified to correlate with a presentation of ASyS, each having manifestations that may slightly differ from others. Despite the proposal of three classification criteria to aid diagnosis, the heterogeneous nature of patient presentations poses challenges. ILD confers a significant burden in patients with ASyS, sometimes manifesting in isolation. Notably, ILD is also often the initial presentation of ASyS, requiring pulmonologists to remain vigilant for an accurate diagnosis. This article will comprehensively review the various aspects of ASyS, including disease presentation, diagnosis, management, and clinical course, with a primary focus on its pulmonary manifestations.

show abstract

Section: Pleural Diseasementioning

confidence: 99%

Review of Pulmonary Manifestations in Antisynthetase Syndrome

Ghanbar,

Danoff

2024

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…Additionally, serum muscle enzymes (such as creatine kinase and aldolase), an antinuclear antibody test, anti-Mi-2, and an anti-Jo-1 antibody are done if the diagnosis of DM or PM has not yet been established ( 129 ). The clinical examination and outcomes of the preliminary tests serve as the basis for further testing (e.g., further antisynthetase antibodies, MDA-5 antibodies which are associated with rapidly progressive ILD, and testing for an overlap syndrome) ( 128 , 130 , 131 ). The diagnosis of ILD in patients with a history of DM and PM can typically be confirmed through a combination of their symptoms, chest imaging (e.g., HRCT), and pulmonary function tests ( 132 ).…”

Section: Connective Tissue Disease-associated Lung Diseasesmentioning

confidence: 99%

Immune-mediated lung diseases: A narrative review

Sweis

Alnaimat

et al. 2023

Front. Med.

View full text Add to dashboard Cite

The role of immunity in the pathogenesis of various pulmonary diseases, particularly interstitial lung diseases (ILDs), is being increasingly appreciated as mechanistic discoveries advance our knowledge in the field. Immune-mediated lung diseases demonstrate clinical and immunological heterogeneity and can be etiologically categorized into connective tissue disease (CTD)-associated, exposure-related, idiopathic, and other miscellaneous lung diseases including sarcoidosis, and post-lung transplant ILD. The immunopathogenesis of many of these diseases remains poorly defined and possibly involves either immune dysregulation, abnormal healing, chronic inflammation, or a combination of these, often in a background of genetic susceptibility. The heterogeneity and complex immunopathogenesis of ILDs complicate management, and thus a collaborative treatment team should work toward an individualized approach to address the unique needs of each patient. Current management of immune-mediated lung diseases is challenging; the choice of therapy is etiology-driven and includes corticosteroids, immunomodulatory drugs such as methotrexate, cyclophosphamide and mycophenolate mofetil, rituximab, or other measures such as discontinuation or avoidance of the inciting agent in exposure-related ILDs. Antifibrotic therapy is approved for some of the ILDs (e.g., idiopathic pulmonary fibrosis) and is being investigated for many others and has shown promising preliminary results. A dire need for advances in the management of immune-mediated lung disease persists in the absence of standardized management guidelines.

show abstract

Antisynthetase Syndrome and Pleural Effusion: A Case Report

Cited by 2 publications

References 0 publications

Review of Pulmonary Manifestations in Antisynthetase Syndrome

Review of Pulmonary Manifestations in Antisynthetase Syndrome

Immune-mediated lung diseases: A narrative review

Contact Info

Product

Resources

About